WM-1119
Based on 15 publication(s) in Google Scholar
WM-1119, a chemical probe, is a highly potent and selective KAT6A inhibitor, with an IC50 of 0.25 μM for KAT6A in lymphoma cells, the binding KD values of WM-1119 with KAT6A, KAT5 and KAT7 are 2 nM, 2.2 μM, 0.5 μM , respectively.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.57%
- No. CAS: 2055397-28-7
- Fòrmula: C18H13F2N3O3S
- Peso molecular:389.38
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) WM-1119
More- Cancer Discov. 2022 Jul 6;12(7):1804-1823. [Abstract]
- Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2024 Jun 5;15(1):4770. [Abstract]
- Adv Sci (Weinh). 2024 Sep;11(34):e2400140. [Abstract]
- Cancer Lett. 2025 Oct 28:631:217946. [Abstract]
- Proc Natl Acad Sci U S A. 2024 Jun 25;121(26):e2405905121. [Abstract]
- Oncogene. 2021 Apr;40(15):2711-2724. [Abstract]
- Leukemia. 2026 Mar 25. [Abstract]
- Cancer Cell Int. 2025 Nov 18;25(1):413. [Abstract]
- Prog Orthod. 2024 Aug 12;25(1):29. [Abstract]
- Biomolecules. 2026 Apr 20;16(4):609. [Abstract]
- bioRxiv. 2025 Sep 20:2025.09.17.676440. [Abstract]
- bioRxiv. 2025 Apr 26:2025.04.23.650241. [Abstract]
- University of Pennsylvania. 2022 Jan 1.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
Flow Cytometry
-
RT-PCR
Actividad biológica
|
MOZ/MORF |
WM-1119 induces cell cycle exit and cellular senescence without causing DNA damage. WM-1119 is 1,100-fold and 250-fold more active against KAT6A than against KAT5 or KAT7, respectively, and so shows greater specificity for KAT6A than does WM-8014. Treatment of MEFs with WM-1119 results in cell cycle arrest in G1 and a senescence phenotype similar to that seen upon treatment with WM-8014. Notably, the activity of WM-1119 in this cell-based assay is an order of magnitude greater than WM-8014 and WM-1119 is able to induce cell cycle arrest at 1 μM. Treatment with WM-1119 inhibits the proliferation of the EMRK1184 lymphoma cells in vitro, WM-1119 (IC50=0.25 μM) is ninefold more active than WM-8014 (IC50=2.3 μM), as expected on the basis of reduced protein binding[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 2055397-28-7
-
Appearance Solid
-
Peso molecular 389.38
-
Fòrmula C18H13F2N3O3S
-
Color Off-white to light yellow
-
SMILES
O=C(NNS(=O)(C1=CC=CC=C1F)=O)C2=CC(C3=NC=CC=C3)=CC(F)=C2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. [Abstract]2022 Jul 6;12(7):1804-1823. PMID: 35499757 -
Cancer Discov
KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. [Abstract]2022 Mar 1;12(3):792-811. PMID: 34853079
WM-1119 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]
WM-1119 (4 μM) treatment induced superoxide anion production and β-galactosidase activity in MOLM-13 cells.
WM-1119 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]
Surface expression of CD11b after treatment of WM-1119 (2 μM; 4 d) in indicatedcell lines.
WM-1119 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]
WM-1119 (4 μM) treatment impaired colony formation ability in MV4;11 and NOMO-1 cells.
WM-1119 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]
WM-1119 (10-20 μM) reduced H3K9ac level in MLL-r primary human AML cells.
WM-1119 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]
WM-1119 (4 μM; 3 d) reduced MYC expression in MLL-r primary human AML cells.
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers. [Abstract]2024 Jun 5;15(1):4770. PMID: 38839769 -
Adv Sci (Weinh)
2024 Sep;11(34):e2400140. PMID: 38973255 -
Cancer Lett
Inhibition of KAT6A enhances immunotherapy efficacy in colorectal cancer by activating interferon response. [Abstract]2025 Oct 28:631:217946. PMID: 40706744 -
Proc Natl Acad Sci U S A
A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes. [Abstract]2024 Jun 25;121(26):e2405905121. PMID: 38889153 -
Oncogene
2021 Apr;40(15):2711-2724. PMID: 33712705 -
Leukemia
A Perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged acute myeloid leukemia. [Abstract]2026 Mar 25. PMID: 41882099 -
Cancer Cell Int
KAT6A acetyltransferase accelerates colorectal cancer progression through upregulating BRD1 protein expression via acetylation modification. [Abstract]2025 Nov 18;25(1):413. PMID: 41254720 -
Prog Orthod
KAT6A/YAP/TEAD4 pathway modulates osteoclastogenesis by regulating the RANKL/OPG ratio on the compression side during orthodontic tooth movement. [Abstract]2024 Aug 12;25(1):29. PMID: 39129034 -
Biomolecules
Lysine Acetyltransferase 6A Drives M1 Macrophage Polarization Through Metabolic Reprogramming in Sepsis-Induced Acute Lung Injury. [Abstract]2026 Apr 20;16(4):609. PMID: 42072730 -
bioRxiv
RESTRICT-seq enables time-gated CRISPR screens and uncovers novel epigenetic dependencies of SCC resistance. [Abstract]2025 Sep 20:2025.09.17.676440. PMID: 41000660 -
bioRxiv
A nuclear branched-chain amino acid catabolism pathway controls histone propionylation in pancreatic cancer. [Abstract]2025 Apr 26:2025.04.23.650241. PMID: 40568091 -
Solvente y solubilidad
DMSO : 125 mg/mL (321.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.42 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Mice[1]
Male C57BL/6-albino (B6(Cg)-Tyrc-2J/J) mice are injected intravenously with 100,000 EMRK1184 cells transfected with a luciferase-expression construct. Lymphoma growth is monitored. Three days after the lymphomacell transplant, all mice show luciferase activity, which indicate the expansion of lymphoma cells. Mice are then divided randomly into WM-1119-treatment with different conentrations (1, 2.5, 5, 10 μM) and vehicle-control groups. Because WM-1119 is rapidly cleared after intraperitoneal injection, with the plasma concentration decreasing to below 1 μM after 4-6 h cohorts of mice are injected every 8 h (three times per day, two cohorts of three mice per treatment group) or every 6 h (four times per day, two cohorts of three and six mice per treatment group)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5682 mL | 12.8409 mL | 25.6819 mL | 64.2046 mL |
| 5 mM | 0.5136 mL | 2.5682 mL | 5.1364 mL | 12.8409 mL | |
| 10 mM | 0.2568 mL | 1.2841 mL | 2.5682 mL | 6.4205 mL | |
| 15 mM | 0.1712 mL | 0.8561 mL | 1.7121 mL | 4.2803 mL | |
| 20 mM | 0.1284 mL | 0.6420 mL | 1.2841 mL | 3.2102 mL | |
| 25 mM | 0.1027 mL | 0.5136 mL | 1.0273 mL | 2.5682 mL | |
| 30 mM | 0.0856 mL | 0.4280 mL | 0.8561 mL | 2.1402 mL | |
| 40 mM | 0.0642 mL | 0.3210 mL | 0.6420 mL | 1.6051 mL | |
| 50 mM | 0.0514 mL | 0.2568 mL | 0.5136 mL | 1.2841 mL | |
| 60 mM | 0.0428 mL | 0.2140 mL | 0.4280 mL | 1.0701 mL | |
| 80 mM | 0.0321 mL | 0.1605 mL | 0.3210 mL | 0.8026 mL | |
| 100 mM | 0.0257 mL | 0.1284 mL | 0.2568 mL | 0.6420 mL |
WM-1119 Related Classifications
HY-102058 Related Classifications
Powered by Bioz